Source author record

Susan Realegeno

Susan Realegeno appears in the imported research catalog. Authorship, coauthor and topic links are available while profile ownership is still unclaimed.

ResearcherUnclaimed source record

Catalog footprint

What is connected

1works
4topics
4close collaborators

Actions

Connect this record

Log in to claim

Research graph

See the researcher in context

Open full explorer

Inspect adjacent papers, topics, institutions and collaborators without losing the researcher page.

Building this map preview

BZPEER is loading the nearby papers, people, topics and institutions for this page.

Published work

1 published item(s)

preprint2020arXiv

An Automated, Cost-Effective Optical System for Accelerated Anti-microbial Susceptibility Testing (AST) using Deep Learning

Antimicrobial susceptibility testing (AST) is a standard clinical procedure used to quantify antimicrobial resistance (AMR). Currently, the gold standard method requires incubation for 18-24 h and subsequent inspection for growth by a trained medical technologist. We demonstrate an automated, cost-effective optical system that delivers early AST results, minimizing incubation time and eliminating human errors, while remaining compatible with standard phenotypic assay workflow. The system is composed of cost-effective components and eliminates the need for optomechanical scanning. A neural network processes the captured optical intensity information from an array of fiber optic cables to determine whether bacterial growth has occurred in each well of a 96-well microplate. When the system was blindly tested on isolates from 33 patients with Staphylococcus aureus infections, 95.03% of all the wells containing growth were correctly identified using our neural network, with an average of 5.72 h of incubation time required to identify growth. 90% of all wells (growth and no-growth) were correctly classified after 7 h, and 95% after 10.5 h. Our deep learning-based optical system met the FDA-defined criteria for essential and categorical agreements for all 14 antibiotics tested after an average of 6.13 h and 6.98 h, respectively. Furthermore, our system met the FDA criteria for major and very major error rates for 11 of 12 possible drugs after an average of 4.02 h, and 9 of 13 possible drugs after an average of 9.39 h, respectively. This system could enable faster, inexpensive, automated AST, especially in resource limited settings, helping to mitigate the rise of global AMR.